The intensity of systemic inflammatory response in patients with chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2013-0-1-38-41
Abstract
Summary. We analyzed plasma level of an inflammatory mediator lipoxin A4 in patients with chronic obstructive pulmonary disease (COPD) which could be used as a marker of systemic inflammation in COPD patients. Relationships between the lipoxin A4 level and cellular markers of inflammation, persistent lipid peroxidation and reduced exercise tolerance have been found. Improvement in lipoxin A4 level could be an attractive contribution to rehabilitation of COPD patients and should be considered in predictive multivariable models of clinical course and in therapeutic algorithms.
About the Authors
T. A. Pertseva
ГУ "Днепропетровская медицинская академия"
Ukraine
Ukraine
N. A. Sanina
ГУ "Украинский государственный НИИ медико/социальных проблем инвалидности Минздрава Украины"
Ukraine
Ukraine
References
1. Chapman K.R., Mannino D.M., Soriano J.B. et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur. Respir. J. 2006; 27: 188–207.
2. Чучалин А.Г. Глобальная стратегия диагностики, лечения и профилактики ХОБЛ (GOLD). М.: Атмосфера; 2007.
3. Ameille J. Occupational chronic obstructive pulmonary disease: a poorly understood disease. Rev. Mal. Respir. 2006; 23 (4): 119–130.
4. Перцева Т.А. Противовоспалительная терапия при ХОБЛ: возможные пути оптимизации. Здоров'я України 2008; 16 (1): 44–45.
5. Фещенко Ю.И., Гаврисюк В.К. Хронические обструктивные заболевания легких: классификация, диагностика, лечение. Ліки України 2004; 7–8: 22–25; 9: 14–17.
6. Авдеев С.Н. Хроническая обструктивная болезнь легких как системное заболевание. Пульмонология 2007; 2: 104–112.
7. Черняев А.Л., Самсонова М.В. Воспаление при хронической обструктивной болезни легких: молекулярные основы патогенеза. Consilium Medicum Ukraina 2011; 5 (1): 9–14.
8. Lee T.H. Lipoxin A4: a novel anti–inflammatory molecule? Thorax 1995; 50 (2): 111–112.
9. McMahon B., Godson C. Lipoxins: endogenous regulators of inflammation. Am. J. Physiol. Renal Physiol. 2004; 286: 189–201.
10. Satoh P.S. 15–epi–Lipoxin A4 ELISA: A Research Tool for Inflammatory Diseases. VP Basic and Exploratory Research, Neogen Corporation / http://www.biocompare.com/Application–Notes/43274–15–epi–Lipoxin–A4–ELISA–A–Research–Tool–For–Inflammatory–Diseases
Review
For citations:
Pertseva T.A., Sanina N.A. The intensity of systemic inflammatory response in patients with chronic obstructive pulmonary disease. PULMONOLOGIYA. 2013;(1):38-41. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-1-38-41
Views:
1111
Email this article 